chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Pulsatile Tinnitus; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6201) via an unspecified route of administration in the left arm on 18Feb2021 (at the age of 48-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 11Mar2021 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Known allergies was reported as not applicable. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included asthma medication (unspecified) from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination.  On an unknown date in 2021, the patient experienced pulsatile tinnitus. The event resulted in doctor or other healthcare professional office/clinic visit. It was unknown whether therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event pulsatile tinnitus was not resolved at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Malaise, Myalgia, Pyrexia
Clinical narrative: Injection Site pain; Tiredness; Headache; Muscle Pain; Feeling Unwell; Feeling Feverish (but no fever); This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 20Mar2021 at 15:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included ards (acute respiratory distress syndrome) survivor and reactive airways disease. The patient had known allergies to mild latex allergy ((rash/hives). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On 21Mar2021 at 01:00, the patient experienced injection site pain, tiredness, headache, muscle pain, feeling unwell and feeling feverish (but no fever). Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of events of injection site pain tiredness, headache, muscle pain, feeling unwell and feeling feverish (but no fever) were recovered on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Injection Site pain; Tiredness; Headache; Muscle Pain; Feeling Unwell; Feeling Feverish (but no fever); This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 20Mar2021 at 15:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included ards (acute respiratory distress syndrome) survivor and reactive airways disease. The patient had known allergies to mild latex allergy ((rash/hives). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On 21Mar2021 at 01:00, the patient experienced injection site pain, tiredness, headache, muscle pain, feeling unwell and feeling feverish (but no fever). Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of events of injection site pain tiredness, headache, muscle pain, feeling unwell and feeling feverish (but no fever) were recovered on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Shingles developed 2 weeks after second vaccine; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 16Apr2021 at 08:00 (at the age of 32-years-old), as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 19Mar2021 at 08:00 (at the age of 32-years-old), as a single dose for COVID-19 immunisation. On 30Apr2021, 2 weeks after second vaccine, the patient developed shingles. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the event and which included treatment with unspecified antiviral medication. The clinical outcome of the event shingles developed 2 weeks after second vaccine was not resolved at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 16.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Headache, Nausea, Pain
Clinical narrative: Bodyache; Light headed; Chills; Headache; Fever; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 16-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 12May2021 at 15:00 (at the age of 16-year-old) as a single dose for COVID-19 immunisation. The patient's medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 14Apr2021 at 14:00 (at the age of 16-year-old) as a single dose for COVID-19 immunisation. On 13May2021 at 06:00, the patient experienced chills, headache, body ache, light headed, fever and nausea. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, headache, body ache, light headed, fever and nausea was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 16.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Bodyache; Light headed; Chills; Headache; Fever; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 16-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 12May2021 at 15:00 (at the age of 16-year-old) as a single dose for COVID-19 immunisation. The patient's medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 14Apr2021 at 14:00 (at the age of 16-year-old) as a single dose for COVID-19 immunisation. On 13May2021 at 06:00, the patient experienced chills, headache, body ache, light headed, fever and nausea. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, headache, body ache, light headed, fever and nausea was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Rubber sensitivity
Clinical narrative: New onset latex allergy; This is a spontaneous report from a contactable nurse, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EP6955) in the right arm on 02Apr2021 and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) in the right arm on 23Apr2021 both (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medication was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in 2021, the patient experienced new onset latex allergy. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event new onset latex allergy was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Arthritis, Gait disturbance, X-ray
Clinical narrative: arthritis; could barely walk; developed terrible joint pain in my shoulders and knees; This is a spontaneous report from a contactable nurse, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9261) via an unspecified route of administration in the left arm on 26Jan2021 at 13:00 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL0142) via an unspecified route of administration in the left arm on 05Jan2021 at 13:00 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. On 31Jan2021 at 15:00, the patient developed terrible joint pain in shoulders and knees to the point where she could barely walk and was diagnosed with arthritis which she never had before. The events lasted roughly four weeks and had subsided almost completely then but it was still not back to normal. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of adverse events joint pain in shoulders and knees to the point where she could barely walk and arthritis which included steroid treatment. On an unknown date, the patient underwent X-ray and the result was arthritis. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events joint pain in shoulders and knees to the point where she could barely walk and arthritis was resolved with sequelae on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Skin rash, whole body; This is a spontaneous report from a non-contactable consumer, the patient. A 38-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 03May2021 at 00:45 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13May2021, ten days after vaccination, the patient experienced skin rash, whole body which was subsidized by taking antihistamine. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of skin rash, whole body which included treatment with antihistamine fexofenadine hydrochloride (ALLEGRA). The clinical outcome of the event skin rash, whole body was resolved on 13May2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Epistaxis
Clinical narrative: Bad nosebleed; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0182) via an unspecified route of administration in the left arm on 12May2021 at 15:00 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient was allergic to shellfish allergy and MSG (monosodium glutamate). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included paracetamol (TYLENOL) and goli ashwaganda supplement (MANUFACTURER UNKNOWN) all for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the left arm in Apr2021 at 09:00 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. On 13May2021 at 09:15, the patient experienced bad nosebleed, which required her to leave her desk and seek paper towels in the bathroom. The nosebleed lasted for about 2 minutes. It was also reported that the patient had experienced extremely rarely every experienced nose bleeding throughout her life. The event resulted in emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event nosebleed was resolved on 13May2021 at 09:17, after the duration of 2 minutes.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Headache
Clinical narrative: Headache; Aching joints; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 22Apr2021 at 15:00 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Medical history included shellfish allergy (shellfish and crustaceans). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included ibuprofen (MOTRIN) from an unknown date for an unknown indication. On 05May2021, two weeks after vaccination, the patient experienced headache and aching joints which was continuing for over a week. Therapeutic measures were not taken as a result of the events headache and aching joints. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache and aching joints were not resolved at the time of this report. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0179) via an unspecified route of administration in the left arm on 13May2021 at 15:00 (at the age of 53-years-old), as a single dose for COVID-19 immunisation.    No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Dizziness, Fatigue, Nausea, Pyrexia
Clinical narrative: Fever; Chills; Nausea; Vomiting; Dizziness; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 12May2021 at 12:00 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had no known allergies. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 20Apr2021 at 12:45 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. On 12May2021 at 23:30, the patient experienced fever, chills, nausea, vomiting, dizziness and fatigue. The events did not result in doctors or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of events. The clinical outcome of the events fever, chills, nausea, vomiting, dizziness and fatigue was not resolved at the time of report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Fever; Chills; Nausea; Vomiting; Dizziness; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 12May2021 at 12:00 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had no known allergies. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 20Apr2021 at 12:45 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. On 12May2021 at 23:30, the patient experienced fever, chills, nausea, vomiting, dizziness and fatigue. The events did not result in doctors or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of events. The clinical outcome of the events fever, chills, nausea, vomiting, dizziness and fatigue was not resolved at the time of report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 13.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Malaise, Migraine, Myalgia
Clinical narrative: Migraine; Sore throat; General malaise; Muscle aches; Fever; Exhaustion; Bouts of sever chills; This is a spontaneous report from a contactable consumer, the parent. A 13-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 12May2021 at 12:00 (at the age of 13-year-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy and COVID-19. The patient did not receive any other medications within two weeks of vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. On 12May2021, the patient experienced sore throat, fever, bouts of severe chills, muscle aches, migraine, exhaustion and general malaise. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore throat, fever, bouts of severe chills, muscle aches, migraine, exhaustion and general malaise was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 13.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Pyrexia
Clinical narrative: Migraine; Sore throat; General malaise; Muscle aches; Fever; Exhaustion; Bouts of sever chills; This is a spontaneous report from a contactable consumer, the parent. A 13-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 12May2021 at 12:00 (at the age of 13-year-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy and COVID-19. The patient did not receive any other medications within two weeks of vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. On 12May2021, the patient experienced sore throat, fever, bouts of severe chills, muscle aches, migraine, exhaustion and general malaise. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore throat, fever, bouts of severe chills, muscle aches, migraine, exhaustion and general malaise was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Mass, Tenderness
Clinical narrative: Small tender lump over collarbone; Small tender lump over collarbone; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0175) via an unspecified route of administration in the left arm on 11May2021 at 13:15 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Other medical history was not reported. Concomitant medications taken within two weeks of vaccination included paracetamol (TYLENOL) and ibuprofen (ADVIL); both from unknown date for unknown indication. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Ew0162), via an unspecified route of administration in the right arm on 20Apr2021 at 13:00 (at the age of 36-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12May2021, the patient experienced a small tender lump over collarbone. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event small tender lump over collarbone was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Slight pain in left arm; This is a spontaneous report from a contactable other healthcare professional, the patient. A 29-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0162) via an unspecified route of administration in the left arm on 13May2021 at 14:30 (at the age of 29-year-old) as a single dose for COVID-19 immunisation. Medical history included protein allergy (Egg protein). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included hydroxyzine (MANUFACTURER UNKNOWN) and escitalopram oxalate (LEXAPRO) both from an unknown date for an unspecified indication. On 13May2021 at 16:00, the patient experienced slight pain in left arm. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event slight pain in left arm was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Nausea, Pyrexia, Vomiting
Clinical narrative: Fever to 101; Nausea; Vomiting; This is a spontaneous report from a contactable physician, the patient. A non-pregnant female patient of unknown age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0182) via an unspecified route of administration in the right arm on 12May2021 at 15:45, as a single dose for COVID-19 immunisation. Medical history included lichen aureus and the patient had allergies to tree nuts, malt barley and dairy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0182) via an unspecified route of administration in the right arm on 21Apr2021 at 15:45, as a single dose for COVID-19 immunisation. On 13May2021 at 10:00, the patient experienced fever to 101 (unspecified unit), nausea for 1 day, and vomiting. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the events which included treatment with unspecified antipyretic. The clinical outcome of the events fever to 101 and vomiting were recovering at the time of this report. The clinical outcome of the event nausea was recovered on 14May2021.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chest pain, Palpitations, Swelling
Clinical narrative: Pain branching out into my left shoulder; Bit of swelling branching out into my left shoulder and upper chest; Pain branching out into my left shoulder and upper chest; Palpitations occurred during the night, waking me up.; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EWO158) via an unspecified route of administration in the left arm on 18Apr2021 at 14:15 (at the age of 45-year-old) and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: WO1832) via an unspecified route of administration in the right arm on 09May2021 at 14:15 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and intestinal trouble. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), amlodipine (MANUFACTURER UNKNOWN) and vitamin d nos (VITAMIN D) on an unknown date for unknown indication and unknown if ongoing. On 19Apr2021 at 01:00, on the following night, the patient felt pain and a bit of swelling branching out into her left shoulder and upper chest. Palpitations occurred during the night, waking her up. She took 2 Acetaminophen. It happened again the next night. The branching pain and swelling occurred off and on for about a week, even during the day. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the event and included treatment with 2 Acetaminophen. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events felt pain and a bit of swelling branching out into left shoulder and upper chest and palpitations were resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swelling of lymph node in the right armpit.; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0182) via an unspecified route of administration in the right arm on 11May2021 at 11:00 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to birch pollen and raw carrots. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0164) via an unspecified route of administration in the right arm on 20Apr2021 at 09:00, as a single dose for COVID-19 immunisation. On 12May2021 at 00:00, the patient experienced swelling of lymph node in the right armpit. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event swelling of lymph node in the right armpit was not recovered at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Cough, Eye pain, Headache, Oropharyngeal pain
Clinical narrative: Sore throat; Sinus pressure; Painful eyes; Cough; Chest tightness; Headache; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration on 07May2021 at 13:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08May2021 at 22:00, the patient experienced sore throat, sinus pressure, painful eyes, cough, chest tightness and headache. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore throat, sinus pressure, painful eyes, cough, chest tightness and headache were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Paranasal sinus discomfort
Clinical narrative: Sore throat; Sinus pressure; Painful eyes; Cough; Chest tightness; Headache; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration on 07May2021 at 13:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08May2021 at 22:00, the patient experienced sore throat, sinus pressure, painful eyes, cough, chest tightness and headache. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore throat, sinus pressure, painful eyes, cough, chest tightness and headache were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash, Urticaria
Clinical narrative: Stinging rash on back of both legs and forearms; Hives on back of armpits.; Uncomfortable and itchy; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ew0151) via an unspecified route of administration in the left arm on 02Apr2021 at 14:30 (at the age of 51-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient did not have any allergies to food, medications, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Apr2021, the patient experienced itch, stinging rash on back of both legs and forearms. The patient also experienced hives on back of armpits. Uncomfortable and itchy. This hives turned into what looked like chicken pox. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of itchy, stinging rash and hives and included treatment with topical steroid. The clinical outcome of the events itchy, stinging rash on back of both legs and forearms (painful rash) and hives on back of armpits were recovering at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal, Headache, Migraine
Clinical narrative: Migraine; foggy most of day or all day; Headache; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the right arm on 18Apr2021 at 10:00 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as not applicable. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take any concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the right arm on 27Mar2021 at 09:00 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. On 19Apr2021 at 08:00, the patient experienced headache, migraine and was foggy most of the day or all day. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, migraine and foggy most of the day or all day were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Aura, Dizziness, Insomnia, Migraine, Nausea
Clinical narrative: Visual aura; Splitting migraine; Migraine that prevented from sleeping; Nauseous; Vaccinated arm very painful; Dizzy; This is a spontaneous report from a contactable consumer, the patient. A 19-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration on 12May2021 (at the age of 19-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID -19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. On an unknown date in May2021, about 11 hours after the first dose, the patient had a visual aura that lasted over 1.5 hours and a splitting migraine that prevented her from sleeping. She was not prone to nausea but was very nauseous right now (at the time of this report). Her vaccinated arm was very painful and she was dizzy. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events visual aura, splitting migraine, migraine that prevented from sleeping, nauseous, vaccinated arm very painful, dizzy were recovering at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Visual aura; Splitting migraine; Migraine that prevented from sleeping; Nauseous; Vaccinated arm very painful; Dizzy; This is a spontaneous report from a contactable consumer, the patient. A 19-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration on 12May2021 (at the age of 19-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID -19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. On an unknown date in May2021, about 11 hours after the first dose, the patient had a visual aura that lasted over 1.5 hours and a splitting migraine that prevented her from sleeping. She was not prone to nausea but was very nauseous right now (at the time of this report). Her vaccinated arm was very painful and she was dizzy. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events visual aura, splitting migraine, migraine that prevented from sleeping, nauseous, vaccinated arm very painful, dizzy were recovering at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Axillary adenopathy from second shot on left arm that has last more than 3 weeks; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 19Apr2021 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included hashimoto's disease and gitelman's syndrome. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on an unknown date, as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021, the patient experienced axillary adenopathy from second shot on left arm that lasted more than 3 weeks, left arm was injection site. The doctor prescribed prednisone to the patient and if adenopathy is not down in one week after steroid, the doctor would order an axillary ultrasound. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the event which included treatment with prednisone. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event axillary adenopathy from second shot on left arm that lasted more than 3 weeks was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Malaise, Myalgia, Pyrexia, Vaccination site pain
Clinical narrative: Tiredness; Muscle pain; Injection site pain; Feeling unwell; Feeling Feverish (but no fever); This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the right arm on 10Apr2021 at 09:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included reactive airway disease, ARDS (acute respiratory distress syndrome) survivor and mild latex allergy (rash/hives). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 20Mar2021 at 15:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. On 10Apr2021 at 18:00, the patient experienced tiredness, muscle pain, injection site pain, feeling unwell and feeling feverish (but no fever). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events tiredness, muscle pain, injection site pain, feeling unwell and feeling feverish (but no fever) were resolved on an unknown date in 2021 at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Mouth injury, Oropharyngeal discomfort
Clinical narrative: Throat and mouth lesions; Throat and mouth lesions; This is a spontaneous report received from a non-contactable consumer or other non hcp. A 27-years-old female patient received 1st dose of bnt162b2 (COMIRNATY,Batch/Lot Number: Unknown), via an unspecified route of administration, administered in Arm Left,at the age of 27 years old,on 19May2021 18:15  as Dose 1,single for covid-19 immunization. Medical history included polycystic ovaries from an unknown date and unknown if ongoing, food allergy from an unknown date and unknown if ongoing Peanuts and tree nuts. Concomitant medications included sertraline hydrochloride (ZOLOFT) taken for an unspecified indication, start and stop date were not reported.The patient experienced throat and mouth lesions and throat and mouth lesions on 19May2021 18:45.The outcome of the event was recovering.The patient had not received any other vaccine within 4 weeks.The patient received Zoloft as medication within 2 weeks.The patient had not received any treatment for adverse events.The patient had not been diagnosed with covid prior vaccination and not tested post vaccination.  No follow-up attempts are possible. Information about lot/batch number cannot be requested. No further information is expected.